<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02024607</url>
  </required_header>
  <id_info>
    <org_study_id>BBI608-246</org_study_id>
    <nct_id>NCT02024607</nct_id>
  </id_info>
  <brief_title>A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer</brief_title>
  <official_title>A Phase Ib/II Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sumitomo Dainippon Pharma Oncology, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sumitomo Dainippon Pharma Oncology, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, multi-center, Phase 1/2 dose escalation study of BBI608 administered&#xD;
      in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with&#xD;
      and without bevacizumab, or regorafenib, or irinotecan.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, multi-center, Phase 1/2 dose escalation study of BBI608 administered&#xD;
      in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with&#xD;
      and without bevacizumab, or regorafenib, or irinotecan. A study cycle will consist of daily&#xD;
      and continuous oral administration of BBI608 for four weeks (28 days) in combination with&#xD;
      FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with and without bevacizumab, or&#xD;
      regorafenib, or irinotecan.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">November 2019</completion_date>
  <primary_completion_date type="Actual">March 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events and Serious Adverse Events</measure>
    <time_frame>The time from the date of first treatment, while the patient is taking napabucasin, and for 30 days after stopping therapy, an average of 4 months.</time_frame>
    <description>Assessment of safety of napabucasin administered in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with and without bevacizumab, or regorafenib, or irinotecan in participants with advanced gastrointestinal malignancies by reporting of adverse events and serious adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Objective Response Rate of Napabucasin Administered in Combination in FOLFIRI in Patients With FOLFIRI/XELIRI-refractory Metastatic Colorectal Cancer</measure>
    <time_frame>From the date of first treatment, every 8 weeks, until the date of first documented objective disease progression, up to 24 months</time_frame>
    <description>Assessment of the objective response rate (ORR) of napabucasin administered in combination with FOLFIRI in patients with FOLFIRI/XELIRI-refractory metastatic colorectal cancer. The Objective Response Rate (ORR) is the proportion of participants with a complete response or partial response who have measurable disease at baseline imaging.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of the Maximum Observed Concentration (Cmax) and Area Under the Plasma Concentration vs. Time Curve (AUClast)</measure>
    <time_frame>Blood samples drawn on days 1, 2, 15, 16, 21, and 22 of the first study cycle</time_frame>
    <description>To determine the maximum concentration of napabucasin and the area under the plasma concentration vs. time curve of napabucasin when administered in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with and without bevacizumab, or regorafenib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>Day 1 of cycle 2</time_frame>
    <description>To determine the response (increase or decrease) of biomarkers from biopsied tumors following the administration of napabucasin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>From the date of first treatment, every 8 weeks, until the date of first documented objective disease progression, up to 24 months.</time_frame>
    <description>To determine the anti-tumor activity (specifically the disease control rate) of napabucasin administered in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with and without bevacizumab, or regorafenib, or irinotecan. Percentage of participants with a documented complete response, partial response and stable disease based on RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate of Patients With FOLFIRI/XELIRI-refractory Metastatic Colorectal Cancer</measure>
    <time_frame>From the date of first treatment, every 8 weeks, until the date of first documented objective disease progression, up to 24 months</time_frame>
    <description>To determine the disease control rate of napabucasin administered in combination with FOLFIRI in patients with FOLFIRI/XELIRI-refractory metastatic colorectal cancer. Percentage of participants with a documented complete response, partial response and stable disease based on RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival of Patients With FOLFIRI/XELIRI-refractory Metastatic Colorectal Cancer</measure>
    <time_frame>The time from the date of first treatment to the date of first documentation of disease progression or death due to any cause, up to thirty six months</time_frame>
    <description>The effect of napabucasin given in combination with FOLFIRI on Progression Free Survival (PFS) of patients with FOLFIRI/XELIRI-refractory metastatic colorectal cancer. PFS of patients with FOLFIRI/XELIRI-refractory metastatic colorectal cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival of Patients With FOLFIRI/XELIRI-refractory Metastatic Colorectal Cancer</measure>
    <time_frame>4 weeks after the patient has been off study treatment, every 3 months thereafter until death, the study closes, up to 36 months.</time_frame>
    <description>The effect of napabucasin given in combination with FOLFIRI on Overall Survival (OS) of patients with FOLFIRI/XELIRI-refractory metastatic colorectal cancer.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">495</enrollment>
  <condition>Advanced Gastrointestinal Cancer</condition>
  <arm_group>
    <arm_group_label>ARM A- BBI608 in combination with FOLFOX6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BBI608 is administered orally twice daily, continuously. Oxaliplatin 85 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following oxaliplatin/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2 over 46-48 hours) continuous intravenous infusion. This regimen will be repeated every 14 days thereafter.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM B- BBI608 in combination with FOLFOX6 and Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BBI608 is administered orally twice daily, continuously. Oxaliplatin 85 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following oxaliplatin/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2 over 46-48 hours) continuous intravenous infusion. Bevacizumab 5 mg/kg will be administered intravenously following oxaliplatin/leucovorin infusion. This regimen will be repeated every 14 days thereafter.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM C- BBI608 in combination with CAPOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BBI608 is administered orally twice daily, continuously. CAPOX regimen will be administered orally (capecitabine) and IV (oxaliplatin). Capecitabine 850 mg/m^2 will be administered orally twice-daily for 14 consecutive days and be repeated every 21 days. Oxaliplatin will be administered IV and be repeated every 21 days thereafter. If capecitabine is tolerated at the 850 mg/m^2 twice daily dose, dosage may be increased to 1000 mg/m^2 twice daily as tolerated after the first cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM D- BBI608 in combination with FOLFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BBI608 is administered orally twice daily, continuously. Irinotecan 180 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2) continuous infusion. This regimen will be repeated every 14 days thereafter.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM E- BBI608 in combination with FOLFIRI and Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BBI608 is administered orally twice daily, continuously. Irinotecan 180 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2) continuous infusion. Bevacizumab 5 mg/kg will be administered intravenously following oxaliplatin/leucovorin infusion. This regimen will be repeated every 14 days thereafter.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM F- BBI608 in combination with Regorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BBI608 is administered orally twice daily, continuously. Regorafenib 120 mg will be administered orally once daily, with a low-fat meal and be continued for 21 consecutive days of every 28 days thereafter. If regorafenib is tolerated in the first cycle, dosage may be increased to 160 mg once daily as tolerated after the first cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm G- BBI608 in combination with Irinotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BBI608 is administered orally twice daily, continuously. Irinotecan 180 mg/m^2 will be administered intravenously. This regimen will be repeated every 14 days thereafter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BBI608</intervention_name>
    <arm_group_label>ARM A- BBI608 in combination with FOLFOX6</arm_group_label>
    <arm_group_label>ARM B- BBI608 in combination with FOLFOX6 and Bevacizumab</arm_group_label>
    <arm_group_label>ARM C- BBI608 in combination with CAPOX</arm_group_label>
    <arm_group_label>ARM D- BBI608 in combination with FOLFIRI</arm_group_label>
    <arm_group_label>ARM E- BBI608 in combination with FOLFIRI and Bevacizumab</arm_group_label>
    <arm_group_label>ARM F- BBI608 in combination with Regorafenib</arm_group_label>
    <arm_group_label>Arm G- BBI608 in combination with Irinotecan</arm_group_label>
    <other_name>Napabucasin</other_name>
    <other_name>BB608</other_name>
    <other_name>BBI-608</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <arm_group_label>ARM A- BBI608 in combination with FOLFOX6</arm_group_label>
    <arm_group_label>ARM B- BBI608 in combination with FOLFOX6 and Bevacizumab</arm_group_label>
    <arm_group_label>ARM D- BBI608 in combination with FOLFIRI</arm_group_label>
    <arm_group_label>ARM E- BBI608 in combination with FOLFIRI and Bevacizumab</arm_group_label>
    <other_name>5-FU</other_name>
    <other_name>Carac</other_name>
    <other_name>Efudex</other_name>
    <other_name>Fluoroplex</other_name>
    <other_name>Adrucil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <arm_group_label>ARM A- BBI608 in combination with FOLFOX6</arm_group_label>
    <arm_group_label>ARM B- BBI608 in combination with FOLFOX6 and Bevacizumab</arm_group_label>
    <arm_group_label>ARM C- BBI608 in combination with CAPOX</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <arm_group_label>ARM A- BBI608 in combination with FOLFOX6</arm_group_label>
    <arm_group_label>ARM B- BBI608 in combination with FOLFOX6 and Bevacizumab</arm_group_label>
    <arm_group_label>ARM D- BBI608 in combination with FOLFIRI</arm_group_label>
    <arm_group_label>ARM E- BBI608 in combination with FOLFIRI and Bevacizumab</arm_group_label>
    <other_name>Folinic Acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <arm_group_label>ARM D- BBI608 in combination with FOLFIRI</arm_group_label>
    <arm_group_label>ARM E- BBI608 in combination with FOLFIRI and Bevacizumab</arm_group_label>
    <arm_group_label>Arm G- BBI608 in combination with Irinotecan</arm_group_label>
    <other_name>Camptosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <arm_group_label>ARM B- BBI608 in combination with FOLFOX6 and Bevacizumab</arm_group_label>
    <arm_group_label>ARM E- BBI608 in combination with FOLFIRI and Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <arm_group_label>ARM C- BBI608 in combination with CAPOX</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib</intervention_name>
    <arm_group_label>ARM F- BBI608 in combination with Regorafenib</arm_group_label>
    <other_name>Stivarga</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed written informed consent&#xD;
&#xD;
          2. A histologically confirmed solid tumor of the gastrointestinal tract including&#xD;
&#xD;
               1. Advanced unresectable, metastatic or recurrent colorectal carcinoma (CRC) for&#xD;
                  which treatment with FOLFOX6 with or without bevacizumab, FOLFIRI with or without&#xD;
                  bevacizumab, CAPOX, or regorafenib would be acceptable as determined by the&#xD;
                  Investigator. FOLFIRI/XELIRI-refractory patients with CRC enrolling on the&#xD;
                  FOLFIRI study arm must have failed treatment with one FOLFIRI pr XELIRI with or&#xD;
                  without bevacizumab regimen for unresectable or metastatic disease. Treatment&#xD;
                  failure is defined as progression of disease (clinical or radiologic) during&#xD;
                  treatment with FOLFIRI with or without bevacizumab or &lt; 3 months after the last&#xD;
                  dose of treatment with FOLFIRI with or without bevacizumab. Patients with CRC&#xD;
                  enrolling on the regorafenib arm of this study will have previously received at&#xD;
                  least two previous lines of therapy for advanced colorectal cancer, and will have&#xD;
                  previously received treatment with a fluoropyrimidine, oxaliplatin, and&#xD;
                  irinotecan. Patients with K-ras wild type tumors enrolling on the regorafenib arm&#xD;
                  will also have previously received either cetuximab or panitumumab.&#xD;
&#xD;
               2. Hepatocellular carcinoma for which treatment with FOLFOX6 or CAPOX would be&#xD;
                  acceptable as determined by the Investigator.&#xD;
&#xD;
               3. Pancreatic adenocarcinoma for which treatment with FOLFOX6, CAPOX, FOLFIRI, or&#xD;
                  irinotecan would be acceptable as determined by the Investigator.&#xD;
&#xD;
               4. Cholangiocarcinoma for which treatment with FOLFOX6 or CAPOX would be acceptable&#xD;
                  as determined by the Investigator.&#xD;
&#xD;
               5. Gastric, GEJ or esophageal adenocarcinoma for which treatment with FOLFOX6,&#xD;
                  CAPOX, FOLFIRI, or irinotecan would be acceptable as determined by the&#xD;
                  Investigator.&#xD;
&#xD;
          3. Patients may be treatment naïve, or may have received standard chemotherapy; including&#xD;
             regimens containing a fluoropyrimidine, or oxaliplatin, or irinotecan, or regorafenib,&#xD;
             or bevacizumab.&#xD;
&#xD;
          4. ≥18 years of age.&#xD;
&#xD;
          5. Karnofsky performance status score ≥70%.&#xD;
&#xD;
          6. Male or female patients of child-producing potential agree to use contraception or&#xD;
             avoidance of pregnancy measures during the study and for 30 days after the last BBI608&#xD;
             dose.&#xD;
&#xD;
          7. Females of childbearing potential have a negative serum pregnancy test.&#xD;
&#xD;
          8. AST level ≤2.5 x ULN and ALT ≤ 2.5 × ULN. For patients with liver metastases, AST ≤3.5&#xD;
             x ULN, and AST ≤3.5 x ULN may be enrolled if agreed upon by the investigator and&#xD;
             medical monitor for the sponsor.&#xD;
&#xD;
          9. Hemoglobin ≥10 g/dl.&#xD;
&#xD;
         10. Total bilirubin level ≤1.5 × ULN.&#xD;
&#xD;
         11. Creatinine ≤1.5 x ULN or creatinine clearance &gt;60 mL/min/1.73 m^2 for patients with&#xD;
             creatinine levels above institutional normal (as determined by Cockcroft-Gault&#xD;
             equation).&#xD;
&#xD;
         12. Absolute neutrophil count ≥ 1.5 x 10^9/L.&#xD;
&#xD;
         13. Platelets ≥100 x 10^9/L.&#xD;
&#xD;
         14. Life expectancy estimated at ≥3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents&#xD;
             within 7 days of the first dose of BBI608.&#xD;
&#xD;
          2. Major surgery within 4 weeks prior to first dose.&#xD;
&#xD;
          3. Any known untreated brain metastases. Treated subjects must be stable for 4 weeks&#xD;
             after completion of that treatment, with image documentation required. Patients must&#xD;
             have no clinical symptoms from brain metastases and must be either off steroids or on&#xD;
             a stable dose of steroids for at least 2 weeks prior to protocol enrollment. Patients&#xD;
             with known leptomeningeal metastases are excluded, even if treated.&#xD;
&#xD;
          4. Pregnant or breastfeeding.&#xD;
&#xD;
          5. Significant gastrointestinal disorder(s) that would, in the opinion of the Principal&#xD;
             Investigator, prevent absorption of an orally available agent&#xD;
&#xD;
          6. Unable or unwilling to swallow BBI608 capsules daily.&#xD;
&#xD;
          7. Prior treatment with BBI608.&#xD;
&#xD;
          8. Uncontrolled intercurrent illness&#xD;
&#xD;
          9. For patients to be treated with a regimen containing 5-fluorouracil/leucovorin:&#xD;
&#xD;
               1. Known hypersensitivity to 5-fluorouracil/leucovorin&#xD;
&#xD;
               2. Known dihydropyrimidine dehydrogenase (DPD) deficiency&#xD;
&#xD;
         10. For patients to be treated with a regimen containing capecitabine:&#xD;
&#xD;
               1. Known hypersensitivity to capecitabine&#xD;
&#xD;
               2. Known dihydropyrimidine dehydrogenase (DPD) deficiency&#xD;
&#xD;
               3. Significant gastrointestinal disorder(s) that would, in the opinion of the&#xD;
                  Principal Investigator, prevent absorption of an orally available agent&#xD;
&#xD;
         11. For patients to be treated with a regimen containing oxaliplatin:&#xD;
&#xD;
               1. Neurosensory neuropathy ≥ grade 2 at baseline&#xD;
&#xD;
               2. Known hypersensitivity to oxaliplatin or other platinum containing compounds&#xD;
&#xD;
         12. For patients to be treated with a regimen containing irinotecan:&#xD;
&#xD;
               1. Known hypersensitivity to irinotecan&#xD;
&#xD;
               2. Abnormal glucuronidation of bilirubin&#xD;
&#xD;
         13. For patients to be treated with a regimen containing bevacizumab:&#xD;
&#xD;
               1. Current uncontrolled hypertension as well as prior history of hypertensive crisis&#xD;
                  or hypertensive encephalopathy&#xD;
&#xD;
               2. History of cardiac disease: congestive heart failure (CHF) &gt; NYHA Class II;&#xD;
                  active coronary artery disease, myocardial infarction within 6 months prior to&#xD;
                  study entry; unevaluated new onset angina within 3 months or unstable angina or&#xD;
                  cardiac arrhythmias requiring anti-arrhythmic therapy&#xD;
&#xD;
               3. History of arterial thrombotic or embolic events (within 6 months prior to study&#xD;
                  entry)&#xD;
&#xD;
               4. Significant vascular disease&#xD;
&#xD;
               5. Evidence of bleeding diathesis or clinically significant coagulopathy&#xD;
&#xD;
               6. Major surgical procedure within 28 days, or anticipation of the need for major&#xD;
                  surgical procedure during the course of the study as well as minor surgical&#xD;
                  procedure within 7 days prior to study enrollment&#xD;
&#xD;
               7. Proteinuria at screening as demonstrated by urinalysis with proteinuria ≥ 2+.&#xD;
&#xD;
               8. History of abdominal fistula, gastrointestinal perforation, peptic ulcer, or&#xD;
                  intra-abdominal abscess within 6 months&#xD;
&#xD;
               9. Ongoing serious, non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
              10. Known hypersensitivity to any component of bevacizumab&#xD;
&#xD;
              11. History of reversible posterior leukoencephalopathy syndrome (RPLS)&#xD;
&#xD;
         14. For patients to be treated with a regimen containing regorafenib:&#xD;
&#xD;
               1. History of cardiac disease: congestive heart failure (CHF) &gt; NYHA Class II;&#xD;
                  active coronary artery disease, myocardial infarction within 6 months prior to&#xD;
                  study entry; unevaluated new onset angina within 3 months or unstable angina or&#xD;
                  cardiac arrhythmias requiring anti-arrhythmic therapy&#xD;
&#xD;
               2. Current uncontrolled hypertension&#xD;
&#xD;
               3. Interstitial lung disease with ongoing signs and symptoms at the time of&#xD;
                  screening&#xD;
&#xD;
               4. History of HIV infection or chronic hepatitis B or C&#xD;
&#xD;
               5. Active clinically serious infections&#xD;
&#xD;
               6. History of arterial or embolic events (within 6 months prior to study entry)&#xD;
&#xD;
               7. Liver cirrhosis ≥ Child-Pugh class B with uncontrolled ascites&#xD;
&#xD;
               8. History of RPLS&#xD;
&#xD;
               9. Ongoing serious, non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
              10. Evidence of bleeding diathesis or a clinically significant coagulopathy&#xD;
&#xD;
              11. Renal failure requiring hemo- or peritoneal dialysis&#xD;
&#xD;
              12. Persistent proteinuria of CTCAE grade 3 (&gt;3.5g/24 hours)&#xD;
&#xD;
              13. Significant gastrointestinal disorder(s) that would, in the opinion of the&#xD;
                  Principal Investigator, prevent absorption of an orally available agent&#xD;
&#xD;
              14. Known hypersensitivity to regorafenib&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boston Biomedical</last_name>
    <role>Study Director</role>
    <affiliation>Sumitomo Dainippon Pharma Oncology, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Campus in Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkview Research Center</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Goshen Center for Cancer Care</name>
      <address>
        <city>Goshen</city>
        <state>Indiana</state>
        <zip>46526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Arnett Hospital</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Ball Memorial Hospital</name>
      <address>
        <city>Muncie</city>
        <state>Indiana</state>
        <zip>47303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care, Inc.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Translational Oncology Research, Greenville Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology - Chattanooga</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology - Nashville</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Cancer Center</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 20, 2013</study_first_submitted>
  <study_first_submitted_qc>December 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2013</study_first_posted>
  <results_first_submitted>July 23, 2021</results_first_submitted>
  <results_first_submitted_qc>August 23, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 20, 2021</results_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 23, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT02024607/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 12, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT02024607/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>495 participants were enrolled between March 2014 and September 2017.</recruitment_details>
      <pre_assignment_details>Participants who died, withdrew consent to survival follow up or were lost to follow up were considered to have completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Napabucasin Plus FOLFOX6</title>
          <description>All participants who were enrolled to Arm A to receive napabucasin administered orally, twice daily, in combination with FOLFOX6 regimen administered every 14 days. The regimen consisted of oxaliplatin 85 mg/m2 together with leucovorin 400 mg/m2 administered intravenously starting on Day 1 of Cycle 1, after the first daily dose of napabucasin. A 5-FU 400 mg/m2 bolus was administered intravenously immediately following oxaliplatin/leucovorin infusion, followed by 5-FU 1200 mg/m2/day (total 2400 mg/m2 over 46-48 hours) by continuous intravenous (IV) infusion.</description>
        </group>
        <group group_id="P2">
          <title>Napabucasin Plus FOLFOX6 Plus Bevacizumab</title>
          <description>All participants who were enrolled to Arm B to receive napabucasin administered orally, twice daily, in combination with FOLFOX6 plus bevacizumab regimen administered every 14 days. The regimen consisted of oxaliplatin 85 mg/m2 together with leucovorin 400 mg/m2 administered intravenously over 2 hours starting on Day1 of Cycle 1, following the first daily dose of napabucasin. A 5-FU 400 mg/m2 bolus was administered intravenously immediately following oxaliplatin/leucovorin infusion, followed by 5-FU 1200 mg/m2/day (total 2400 mg/m2 over 46-48 hours) by continuous IV infusion. Bevacizumab 5 mg/kg was administered intravenously following the oxaliplatin/leucovorin infusion.</description>
        </group>
        <group group_id="P3">
          <title>Napabucasin Plus CAPOX</title>
          <description>All participants who were enrolled to Arm C to receive napabucasin administered orally, twice daily, in combination with CAPOX regimen. The CAPOX regimen was administered orally (capecitabine) and by IV (oxaliplatin). Starting on Day 1 of Cycle 1, capecitabine 850 mg/m2 was administered orally BID following the first daily dose of napabucasin for 14 consecutive days and repeated every 21 days. Oxaliplatin 130 mg/m2 was administered intravenously over 2 hours, following the first daily dose of napabucasin starting on Day 1 of Cycle 1 and repeated every 21 days thereafter. If capecitabine was tolerated at the 850 mg/m2 BID dose, the dosage could have been increased to 1000 mg/m2 BID as tolerated after the first cycle.</description>
        </group>
        <group group_id="P4">
          <title>Napabucasin Plus FOLFIRI</title>
          <description>All participants who were enrolled to Arm D to receive napabucasin administered orally, twice daily, in combination with FOLFIRI regimen. Irinotecan 180 mg/m2 together with leucovorin 400 mg/m2 was administered intravenously starting on Day 1 of Cycle 1, following the first dose of napabucasin. A 5-FU 400 mg/m2 bolus was administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m2/day (total 2400 mg/m2) by continuous infusion. This regimen was repeated every 14 days thereafter.</description>
        </group>
        <group group_id="P5">
          <title>Napabucasin Plus FOLFIRI Plus Bevacizumab</title>
          <description>All participants who were enrolled to Arm E to receive napabucasin administered orally, twice daily, in combination with FOLFIRI plus bevacizumab regimen. Irinotecan 180 mg/m2 together with leucovorin 400 mg/m2 was administered intravenously starting on Day 1 of Cycle 1, following the first dose of napabucasin. A 5-FU 400 mg/m2 bolus was administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5 FU 1200 mg/m2/day (total 2400 mg/m2) by continuous infusion. Bevacizumab 5 mg/kg was administered intravenously following the irinotecan/leucovorin infusion. This regimen was repeated every 14 days thereafter.</description>
        </group>
        <group group_id="P6">
          <title>Napabucasin Plus Regorafenib</title>
          <description>All participants who were enrolled to Arm F to receive napabucasin administered orally, twice daily, in combination with regorafenib 120 mg, administered orally once daily with a low-fat meal, starting on Day 1 of Cycle 1 for 21 consecutive days of every 28 days thereafter. If regorafenib was tolerated in the first cycle, the dosage could have been increased to 160 mg once daily as tolerated after the first cycle.</description>
        </group>
        <group group_id="P7">
          <title>Napabucasin Plus Irinotecan</title>
          <description>All participants who were enrolled to Arm G to receive napabucasin administered orally, twice daily, in combination with irinotecan 180 mg/m2, administered intravenously starting on Day 1 of Cycle 1, following the first dose of napabucasin. This regimen was repeated every 14 days thereafter.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="87"/>
                <participants group_id="P4" count="156"/>
                <participants group_id="P5" count="40"/>
                <participants group_id="P6" count="54"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="87"/>
                <participants group_id="P4" count="156"/>
                <participants group_id="P5" count="40"/>
                <participants group_id="P6" count="54"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Napabucasin Plus FOLFOX6</title>
          <description>All participants who were enrolled to Arm A to receive napabucasin administered orally, twice daily, in combination with FOLFOX6 regimen administered every 14 days. The regimen consisted of oxaliplatin 85 mg/m2 together with leucovorin 400 mg/m2 administered intravenously starting on Day 1 of Cycle 1, after the first daily dose of napabucasin. A 5-FU 400 mg/m2 bolus was administered intravenously immediately following oxaliplatin/leucovorin infusion, followed by 5-FU 1200 mg/m2/day (total 2400 mg/m2 over 46-48 hours) by continuous intravenous (IV) infusion.</description>
        </group>
        <group group_id="B2">
          <title>Napabucasin Plus FOLFOX6 Plus Bevacizumab</title>
          <description>All participants who were enrolled to Arm B to receive napabucasin administered orally, twice daily, in combination with FOLFOX6 plus bevacizumab regimen administered every 14 days. The regimen consisted of oxaliplatin 85 mg/m2 together with leucovorin 400 mg/m2 administered intravenously over 2 hours starting on Day1 of Cycle 1, following the first daily dose of napabucasin. A 5-FU 400 mg/m2 bolus was administered intravenously immediately following oxaliplatin/leucovorin infusion, followed by 5-FU 1200 mg/m2/day (total 2400 mg/m2 over 46-48 hours) by continuous IV infusion. Bevacizumab 5 mg/kg was administered intravenously following the oxaliplatin/leucovorin infusion.</description>
        </group>
        <group group_id="B3">
          <title>Napabucasin Plus CAPOX</title>
          <description>All participants who were enrolled to Arm C to receive napabucasin administered orally, twice daily, in combination with CAPOX regimen. The CAPOX regimen was administered orally (capecitabine) and by IV (oxaliplatin). Starting on Day 1 of Cycle 1, capecitabine 850 mg/m2 was administered orally BID following the first daily dose of napabucasin for 14 consecutive days and repeated every 21 days. Oxaliplatin 130 mg/m2 was administered intravenously over 2 hours, following the first daily dose of napabucasin starting on Day 1 of Cycle 1 and repeated every 21 days thereafter. If capecitabine was tolerated at the 850 mg/m2 BID dose, the dosage could have been increased to 1000 mg/m2 BID as tolerated after the first cycle.</description>
        </group>
        <group group_id="B4">
          <title>Napabucasin Plus FOLFIRI</title>
          <description>All participants who were enrolled to Arm D to receive napabucasin administered orally, twice daily, in combination with FOLFIRI regimen. Irinotecan 180 mg/m2 together with leucovorin 400 mg/m2 was administered intravenously starting on Day 1 of Cycle 1, following the first dose of napabucasin. A 5-FU 400 mg/m2 bolus was administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m2/day (total 2400 mg/m2) by continuous infusion. This regimen was repeated every 14 days thereafter.</description>
        </group>
        <group group_id="B5">
          <title>Napabucasin Plus FOLFIRI Plus Bevacizumab</title>
          <description>All participants who were enrolled to Arm E to receive napabucasin administered orally, twice daily, in combination with FOLFIRI plus bevacizumab regimen. Irinotecan 180 mg/m2 together with leucovorin 400 mg/m2 was administered intravenously starting on Day 1 of Cycle 1, following the first dose of napabucasin. A 5-FU 400 mg/m2 bolus was administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5 FU 1200 mg/m2/day (total 2400 mg/m2) by continuous infusion. Bevacizumab 5 mg/kg was administered intravenously following the irinotecan/leucovorin infusion. This regimen was repeated every 14 days thereafter.</description>
        </group>
        <group group_id="B6">
          <title>Napabucasin Plus Regorafenib</title>
          <description>All participants who were enrolled to Arm F to receive napabucasin administered orally, twice daily, in combination with regorafenib 120 mg, administered orally once daily with a low-fat meal, starting on Day 1 of Cycle 1 for 21 consecutive days of every 28 days thereafter. If regorafenib was tolerated in the first cycle, the dosage could have been increased to 160 mg once daily as tolerated after the first cycle.</description>
        </group>
        <group group_id="B7">
          <title>Napabucasin Plus Irinotecan</title>
          <description>All participants who were enrolled to Arm G to receive napabucasin administered orally, twice daily, in combination with irinotecan 180 mg/m2, administered intravenously starting on Day 1 of Cycle 1, following the first dose of napabucasin. This regimen was repeated every 14 days thereafter.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="115"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="87"/>
            <count group_id="B4" value="156"/>
            <count group_id="B5" value="40"/>
            <count group_id="B6" value="54"/>
            <count group_id="B7" value="2"/>
            <count group_id="B8" value="495"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.6" spread="9.26"/>
                    <measurement group_id="B2" value="55.4" spread="13.54"/>
                    <measurement group_id="B3" value="62.7" spread="11.69"/>
                    <measurement group_id="B4" value="58.3" spread="12.18"/>
                    <measurement group_id="B5" value="55.8" spread="7.25"/>
                    <measurement group_id="B6" value="57.5" spread="11.56"/>
                    <measurement group_id="B7" value="73.0" spread="1.41"/>
                    <measurement group_id="B8" value="59.4" spread="11.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="52"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="28"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="189"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="104"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="26"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="134"/>
                    <measurement group_id="B5" value="35"/>
                    <measurement group_id="B6" value="49"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events and Serious Adverse Events</title>
        <description>Assessment of safety of napabucasin administered in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with and without bevacizumab, or regorafenib, or irinotecan in participants with advanced gastrointestinal malignancies by reporting of adverse events and serious adverse events</description>
        <time_frame>The time from the date of first treatment, while the patient is taking napabucasin, and for 30 days after stopping therapy, an average of 4 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Napabucasin Plus FOLFOX6</title>
            <description>Napabucasin administered orally, twice daily, in combination with FOLFOX6 regimen administered every 14 days. The regimen consisted of oxaliplatin 85 mg/m2 together with leucovorin 400 mg/m2 administered intravenously starting on Day 1 of Cycle 1, after the first daily dose of napabucasin. A 5-FU 400 mg/m2 bolus was administered intravenously immediately following oxaliplatin/leucovorin infusion, followed by 5-FU 1200 mg/m2/day (total 2400 mg/m2 over 46-48 hours) by continuous intravenous (IV) infusion. Patients included in this group received at least one dose of study drug.</description>
          </group>
          <group group_id="O2">
            <title>Napabucasin Plus FOLFOX6 Plus Bevacizumab</title>
            <description>Napabucasin administered orally, twice daily, in combination with FOLFOX6 plus bevacizumab regimen administered every 14 days. The regimen consisted of oxaliplatin 85 mg/m2 together with leucovorin 400 mg/m2 administered intravenously over 2 hours starting on Day1 of Cycle 1, following the first daily dose of napabucasin. A 5-FU 400 mg/m2 bolus was administered intravenously immediately following oxaliplatin/leucovorin infusion, followed by 5-FU 1200 mg/m2/day (total 2400 mg/m2 over 46-48 hours) by continuous IV infusion. Bevacizumab 5 mg/kg was administered intravenously following the oxaliplatin/leucovorin infusion. Patients included in this group received at least one dose of study drug.</description>
          </group>
          <group group_id="O3">
            <title>Napabucasin Plus CAPOX</title>
            <description>Napabucasin administered orally, twice daily, in combination with CAPOX regimen. The CAPOX regimen was administered orally (capecitabine) and by IV (oxaliplatin). Starting on Day 1 of Cycle 1, capecitabine 850 mg/m2 was administered orally BID following the first daily dose of napabucasin for 14 consecutive days and repeated every 21 days. Oxaliplatin 130 mg/m2 was administered intravenously over 2 hours, following the first daily dose of napabucasin starting on Day 1 of Cycle 1 and repeated every 21 days thereafter. If capecitabine was tolerated at the 850 mg/m2 BID dose, the dosage could have been increased to 1000 mg/m2 BID as tolerated after the first cycle. Patients included in this group received at least one dose of study drug.</description>
          </group>
          <group group_id="O4">
            <title>Napabucasin Plus FOLFIRI</title>
            <description>Napabucasin administered orally, twice daily, in combination with FOLFIRI regimen. Irinotecan 180 mg/m2 together with leucovorin 400 mg/m2 was administered intravenously starting on Day 1 of Cycle 1, following the first dose of napabucasin. A 5-FU 400 mg/m2 bolus was administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m2/day (total 2400 mg/m2) by continuous infusion. This regimen was repeated every 14 days thereafter. Patients included in this group received at least one dose of study drug.</description>
          </group>
          <group group_id="O5">
            <title>Napabucasin Plus FOLFIRI Plus Bevacizumab</title>
            <description>Napabucasin administered orally, twice daily, in combination with FOLFIRI plus bevacizumab regimen. Irinotecan 180 mg/m2 together with leucovorin 400 mg/m2 was administered intravenously starting on Day 1 of Cycle 1, following the first dose of napabucasin. A 5-FU 400 mg/m2 bolus was administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5 FU 1200 mg/m2/day (total 2400 mg/m2) by continuous infusion. Bevacizumab 5 mg/kg was administered intravenously following the irinotecan/leucovorin infusion. This regimen was repeated every 14 days thereafter. Patients included in this group received at least one dose of study drug.</description>
          </group>
          <group group_id="O6">
            <title>Napabucasin Plus Regorafenib</title>
            <description>Napabucasin administered orally, twice daily, in combination with regorafenib 120 mg, administered orally once daily with a low-fat meal, starting on Day 1 of Cycle 1 for 21 consecutive days of every 28 days thereafter. If regorafenib was tolerated in the first cycle, the dosage could have been increased to 160 mg once daily as tolerated after the first cycle. Patients included in this group received at least one dose of study drug.</description>
          </group>
          <group group_id="O7">
            <title>Napabucasin Plus Irinotecan</title>
            <description>Napabucasin administered orally, twice daily, in combination with irinotecan 180 mg/m2, administered intravenously starting on Day 1 of Cycle 1, following the first dose of napabucasin. This regimen was repeated every 14 days thereafter. Patients included in this group received at least one dose of study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events and Serious Adverse Events</title>
          <description>Assessment of safety of napabucasin administered in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with and without bevacizumab, or regorafenib, or irinotecan in participants with advanced gastrointestinal malignancies by reporting of adverse events and serious adverse events</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="156"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="87"/>
                    <measurement group_id="O4" value="156"/>
                    <measurement group_id="O5" value="40"/>
                    <measurement group_id="O6" value="54"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Objective Response Rate of Napabucasin Administered in Combination in FOLFIRI in Patients With FOLFIRI/XELIRI-refractory Metastatic Colorectal Cancer</title>
        <description>Assessment of the objective response rate (ORR) of napabucasin administered in combination with FOLFIRI in patients with FOLFIRI/XELIRI-refractory metastatic colorectal cancer. The Objective Response Rate (ORR) is the proportion of participants with a complete response or partial response who have measurable disease at baseline imaging.</description>
        <time_frame>From the date of first treatment, every 8 weeks, until the date of first documented objective disease progression, up to 24 months</time_frame>
        <population>Analysis limited to a subset of group D in which patients had FOLFIRI/XELIRI refractory metastatic colorectal cancer. Patients in this subgroup also had a baseline scan and at least 1 disease assessment following the initiation of therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Napabucasin Plus FOLFIRI</title>
            <description>Napabucasin administered orally, twice daily, in combination with FOLFIRI regimen. Irinotecan 180 mg/m2 together with leucovorin 400 mg/m2 was administered intravenously starting on Day 1 of Cycle 1, following the first dose of napabucasin. A 5-FU 400 mg/m2 bolus was administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m2/day (total 2400 mg/m2) by continuous infusion. This regimen was repeated every 14 days thereafter . Patients in this group had a baseline scan and at least one assessment approximately 8 weeks from baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>The Objective Response Rate of Napabucasin Administered in Combination in FOLFIRI in Patients With FOLFIRI/XELIRI-refractory Metastatic Colorectal Cancer</title>
          <description>Assessment of the objective response rate (ORR) of napabucasin administered in combination with FOLFIRI in patients with FOLFIRI/XELIRI-refractory metastatic colorectal cancer. The Objective Response Rate (ORR) is the proportion of participants with a complete response or partial response who have measurable disease at baseline imaging.</description>
          <population>Analysis limited to a subset of group D in which patients had FOLFIRI/XELIRI refractory metastatic colorectal cancer. Patients in this subgroup also had a baseline scan and at least 1 disease assessment following the initiation of therapy.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determination of the Maximum Observed Concentration (Cmax) and Area Under the Plasma Concentration vs. Time Curve (AUClast)</title>
        <description>To determine the maximum concentration of napabucasin and the area under the plasma concentration vs. time curve of napabucasin when administered in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with and without bevacizumab, or regorafenib.</description>
        <time_frame>Blood samples drawn on days 1, 2, 15, 16, 21, and 22 of the first study cycle</time_frame>
        <population>Sponsor's decision to terminate further development of the napabucasin program. Data collection and analysis were therefore not conducted as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>Napabucasin Plus FOLFOX6</title>
            <description>Napabucasin administered orally, twice daily, in combination with FOLFOX6 regimen administered every 14 days. The regimen consisted of oxaliplatin 85 mg/m2 together with leucovorin 400 mg/m2 administered intravenously starting on Day 1 of Cycle 1, after the first daily dose of napabucasin. A 5-FU 400 mg/m2 bolus was administered intravenously immediately following oxaliplatin/leucovorin infusion, followed by 5-FU 1200 mg/m2/day (total 2400 mg/m2 over 46-48 hours) by continuous intravenous (IV) infusion. Patients included in this group received at least one dose of study drug.</description>
          </group>
          <group group_id="O2">
            <title>Napabucasin Plus FOLFOX6 Plus Bevacizumab</title>
            <description>Napabucasin administered orally, twice daily, in combination with FOLFOX6 plus bevacizumab regimen administered every 14 days. The regimen consisted of oxaliplatin 85 mg/m2 together with leucovorin 400 mg/m2 administered intravenously over 2 hours starting on Day1 of Cycle 1, following the first daily dose of napabucasin. A 5-FU 400 mg/m2 bolus was administered intravenously immediately following oxaliplatin/leucovorin infusion, followed by 5-FU 1200 mg/m2/day (total 2400 mg/m2 over 46-48 hours) by continuous IV infusion. Bevacizumab 5 mg/kg was administered intravenously following the oxaliplatin/leucovorin infusion. Patients included in this group received at least one dose of study drug.</description>
          </group>
          <group group_id="O3">
            <title>Napabucasin Plus CAPOX</title>
            <description>Napabucasin administered orally, twice daily, in combination with CAPOX regimen. The CAPOX regimen was administered orally (capecitabine) and by IV (oxaliplatin). Starting on Day 1 of Cycle 1, capecitabine 850 mg/m2 was administered orally BID following the first daily dose of napabucasin for 14 consecutive days and repeated every 21 days. Oxaliplatin 130 mg/m2 was administered intravenously over 2 hours, following the first daily dose of napabucasin starting on Day 1 of Cycle 1 and repeated every 21 days thereafter. If capecitabine was tolerated at the 850 mg/m2 BID dose, the dosage could have been increased to 1000 mg/m2 BID as tolerated after the first cycle. Patients included in this group received at least one dose of study drug.</description>
          </group>
          <group group_id="O4">
            <title>Napabucasin Plus FOLFIRI</title>
            <description>Napabucasin administered orally, twice daily, in combination with FOLFIRI regimen. Irinotecan 180 mg/m2 together with leucovorin 400 mg/m2 was administered intravenously starting on Day 1 of Cycle 1, following the first dose of napabucasin. A 5-FU 400 mg/m2 bolus was administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m2/day (total 2400 mg/m2) by continuous infusion. This regimen was repeated every 14 days thereafter. Patients included in this group received at least one dose of study drug.</description>
          </group>
          <group group_id="O5">
            <title>Napabucasin Plus FOLFIRI Plus Bevacizumab</title>
            <description>Napabucasin administered orally, twice daily, in combination with FOLFIRI plus bevacizumab regimen. Irinotecan 180 mg/m2 together with leucovorin 400 mg/m2 was administered intravenously starting on Day 1 of Cycle 1, following the first dose of napabucasin. A 5-FU 400 mg/m2 bolus was administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5 FU 1200 mg/m2/day (total 2400 mg/m2) by continuous infusion. Bevacizumab 5 mg/kg was administered intravenously following the irinotecan/leucovorin infusion. This regimen was repeated every 14 days thereafter. Patients included in this group received at least one dose of study drug.</description>
          </group>
          <group group_id="O6">
            <title>Napabucasin Plus Regorafenib</title>
            <description>Napabucasin administered orally, twice daily, in combination with regorafenib 120 mg, administered orally once daily with a low-fat meal, starting on Day 1 of Cycle 1 for 21 consecutive days of every 28 days thereafter. If regorafenib was tolerated in the first cycle, the dosage could have been increased to 160 mg once daily as tolerated after the first cycle. Patients included in this group received at least one dose of study drug.</description>
          </group>
          <group group_id="O7">
            <title>Napabucasin Plus Irinotecan</title>
            <description>Napabucasin administered orally, twice daily, in combination with irinotecan 180 mg/m2, administered intravenously starting on Day 1 of Cycle 1, following the first dose of napabucasin. This regimen was repeated every 14 days thereafter. Patients included in this group received at least one dose of study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Determination of the Maximum Observed Concentration (Cmax) and Area Under the Plasma Concentration vs. Time Curve (AUClast)</title>
          <description>To determine the maximum concentration of napabucasin and the area under the plasma concentration vs. time curve of napabucasin when administered in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with and without bevacizumab, or regorafenib.</description>
          <population>Sponsor's decision to terminate further development of the napabucasin program. Data collection and analysis were therefore not conducted as planned.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics</title>
        <description>To determine the response (increase or decrease) of biomarkers from biopsied tumors following the administration of napabucasin</description>
        <time_frame>Day 1 of cycle 2</time_frame>
        <population>No on-treatment biopsies were performed therefore no pharmacodynamic testing on tumor tissue was conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Napabucasin Plus FOLFOX6</title>
            <description>All participants who were enrolled to Arm A to receive napabucasin administered orally, twice daily, in combination with FOLFOX6 regimen administered every 14 days. The regimen consisted of oxaliplatin 85 mg/m2 together with leucovorin 400 mg/m2 administered intravenously starting on Day 1 of Cycle 1, after the first daily dose of napabucasin. A 5-FU 400 mg/m2 bolus was administered intravenously immediately following oxaliplatin/leucovorin infusion, followed by 5-FU 1200 mg/m2/day (total 2400 mg/m2 over 46-48 hours) by continuous intravenous (IV) infusion.</description>
          </group>
          <group group_id="O2">
            <title>Napabucasin Plus FOLFOX6 Plus Bevacizumab</title>
            <description>All participants who were enrolled to Arm B to receive napabucasin administered orally, twice daily, in combination with FOLFOX6 plus bevacizumab regimen administered every 14 days. The regimen consisted of oxaliplatin 85 mg/m2 together with leucovorin 400 mg/m2 administered intravenously over 2 hours starting on Day1 of Cycle 1, following the first daily dose of napabucasin. A 5-FU 400 mg/m2 bolus was administered intravenously immediately following oxaliplatin/leucovorin infusion, followed by 5-FU 1200 mg/m2/day (total 2400 mg/m2 over 46-48 hours) by continuous IV infusion. Bevacizumab 5 mg/kg was administered intravenously following the oxaliplatin/leucovorin infusion.</description>
          </group>
          <group group_id="O3">
            <title>Napabucasin Plus CAPOX</title>
            <description>All participants who were enrolled to Arm C to receive napabucasin administered orally, twice daily, in combination with CAPOX regimen. The CAPOX regimen was administered orally (capecitabine) and by IV (oxaliplatin). Starting on Day 1 of Cycle 1, capecitabine 850 mg/m2 was administered orally BID following the first daily dose of napabucasin for 14 consecutive days and repeated every 21 days. Oxaliplatin 130 mg/m2 was administered intravenously over 2 hours, following the first daily dose of napabucasin starting on Day 1 of Cycle 1 and repeated every 21 days thereafter. If capecitabine was tolerated at the 850 mg/m2 BID dose, the dosage could have been increased to 1000 mg/m2 BID as tolerated after the first cycle.</description>
          </group>
          <group group_id="O4">
            <title>Napabucasin Plus FOLFIRI</title>
            <description>All participants who were enrolled to Arm D to receive napabucasin administered orally, twice daily, in combination with FOLFIRI regimen. Irinotecan 180 mg/m2 together with leucovorin 400 mg/m2 was administered intravenously starting on Day 1 of Cycle 1, following the first dose of napabucasin. A 5-FU 400 mg/m2 bolus was administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m2/day (total 2400 mg/m2) by continuous infusion. This regimen was repeated every 14 days thereafter.</description>
          </group>
          <group group_id="O5">
            <title>Napabucasin Plus FOLFIRI Plus Bevacizumab</title>
            <description>All participants who were enrolled to Arm E to receive napabucasin administered orally, twice daily, in combination with FOLFIRI plus bevacizumab regimen. Irinotecan 180 mg/m2 together with leucovorin 400 mg/m2 was administered intravenously starting on Day 1 of Cycle 1, following the first dose of napabucasin. A 5-FU 400 mg/m2 bolus was administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5 FU 1200 mg/m2/day (total 2400 mg/m2) by continuous infusion. Bevacizumab 5 mg/kg was administered intravenously following the irinotecan/leucovorin infusion. This regimen was repeated every 14 days thereafter.</description>
          </group>
          <group group_id="O6">
            <title>Napabucasin Plus Regorafenib</title>
            <description>All participants who were enrolled to Arm F to receive napabucasin administered orally, twice daily, in combination with regorafenib 120 mg, administered orally once daily with a low-fat meal, starting on Day 1 of Cycle 1 for 21 consecutive days of every 28 days thereafter. If regorafenib was tolerated in the first cycle, the dosage could have been increased to 160 mg once daily as tolerated after the first cycle.</description>
          </group>
          <group group_id="O7">
            <title>Napabucasin Plus Irinotecan</title>
            <description>All participants who were enrolled to Arm G to receive napabucasin administered orally, twice daily, in combination with irinotecan 180 mg/m2, administered intravenously starting on Day 1 of Cycle 1, following the first dose of napabucasin. This regimen was repeated every 14 days thereafter.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics</title>
          <description>To determine the response (increase or decrease) of biomarkers from biopsied tumors following the administration of napabucasin</description>
          <population>No on-treatment biopsies were performed therefore no pharmacodynamic testing on tumor tissue was conducted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Control Rate</title>
        <description>To determine the anti-tumor activity (specifically the disease control rate) of napabucasin administered in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with and without bevacizumab, or regorafenib, or irinotecan. Percentage of participants with a documented complete response, partial response and stable disease based on RECIST 1.1.</description>
        <time_frame>From the date of first treatment, every 8 weeks, until the date of first documented objective disease progression, up to 24 months.</time_frame>
        <population>Patients who received at least 1 cycle of study treatment and had at least 1 disease assessment following the initiation of therapy. Patients missing imaging assessment following the initiation of treatment are not included in the assessment for DCR.</population>
        <group_list>
          <group group_id="O1">
            <title>Napabucasin Plus FOLFOX6</title>
            <description>Napabucasin administered orally, twice daily, in combination with FOLFOX6 regimen administered every 14 days. The regimen consisted of oxaliplatin 85 mg/m2 together with leucovorin 400 mg/m2 administered intravenously starting on Day 1 of Cycle 1, after the first daily dose of napabucasin. A 5-FU 400 mg/m2 bolus was administered intravenously immediately following oxaliplatin/leucovorin infusion, followed by 5-FU 1200 mg/m2/day (total 2400 mg/m2 over 46-48 hours) by continuous intravenous (IV) infusion. Patients in this group had a baseline scan and at least one assessment approximately 8 weeks from baseline.</description>
          </group>
          <group group_id="O2">
            <title>Napabucasin Plus FOLFOX6 Plus Bevacizumab</title>
            <description>All participants who were enrolled to Arm B to receive napabucasin administered orally, twice daily, in combination with FOLFOX6 plus bevacizumab regimen administered every 14 days. The regimen consisted of oxaliplatin 85 mg/m2 together with leucovorin 400 mg/m2 administered intravenously over 2 hours starting on Day1 of Cycle 1, following the first daily dose of napabucasin. A 5-FU 400 mg/m2 bolus was administered intravenously immediately following oxaliplatin/leucovorin infusion, followed by 5-FU 1200 mg/m2/day (total 2400 mg/m2 over 46-48 hours) by continuous IV infusion. Bevacizumab 5 mg/kg was administered intravenously following the oxaliplatin/leucovorin infusion. Patients in this group had a baseline scan and at least one assessment approximately 8 weeks from baseline.</description>
          </group>
          <group group_id="O3">
            <title>Napabucasin Plus CAPOX</title>
            <description>All participants who were enrolled to Arm C to receive napabucasin administered orally, twice daily, in combination with CAPOX regimen. The CAPOX regimen was administered orally (capecitabine) and by IV (oxaliplatin). Starting on Day 1 of Cycle 1, capecitabine 850 mg/m2 was administered orally BID following the first daily dose of napabucasin for 14 consecutive days and repeated every 21 days. Oxaliplatin 130 mg/m2 was administered intravenously over 2 hours, following the first daily dose of napabucasin starting on Day 1 of Cycle 1 and repeated every 21 days thereafter. If capecitabine was tolerated at the 850 mg/m2 BID dose, the dosage could have been increased to 1000 mg/m2 BID as tolerated after the first cycle. Patients in this group had a baseline scan and at least one assessment approximately 8 weeks from baseline.</description>
          </group>
          <group group_id="O4">
            <title>Napabucasin Plus FOLFIRI</title>
            <description>All participants who were enrolled to Arm D to receive napabucasin administered orally, twice daily, in combination with FOLFIRI regimen. Irinotecan 180 mg/m2 together with leucovorin 400 mg/m2 was administered intravenously starting on Day 1 of Cycle 1, following the first dose of napabucasin. A 5-FU 400 mg/m2 bolus was administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m2/day (total 2400 mg/m2) by continuous infusion. This regimen was repeated every 14 days thereafter. Patients in this group had a baseline scan and at least one assessment approximately 8 weeks from baseline.</description>
          </group>
          <group group_id="O5">
            <title>Napabucasin Plus FOLFIRI Plus Bevacizumab</title>
            <description>All participants who were enrolled to Arm E to receive napabucasin administered orally, twice daily, in combination with FOLFIRI plus bevacizumab regimen. Irinotecan 180 mg/m2 together with leucovorin 400 mg/m2 was administered intravenously starting on Day 1 of Cycle 1, following the first dose of napabucasin. A 5-FU 400 mg/m2 bolus was administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5 FU 1200 mg/m2/day (total 2400 mg/m2) by continuous infusion. Bevacizumab 5 mg/kg was administered intravenously following the irinotecan/leucovorin infusion. This regimen was repeated every 14 days thereafter. Patients in this group had a baseline scan and at least one assessment approximately 8 weeks from baseline.</description>
          </group>
          <group group_id="O6">
            <title>Napabucasin Plus Regorafenib</title>
            <description>All participants who were enrolled to Arm F to receive napabucasin administered orally, twice daily, in combination with regorafenib 120 mg, administered orally once daily with a low-fat meal, starting on Day 1 of Cycle 1 for 21 consecutive days of every 28 days thereafter. If regorafenib was tolerated in the first cycle, the dosage could have been increased to 160 mg once daily as tolerated after the first cycle. Patients in this group had a baseline scan and at least one assessment approximately 8 weeks from baseline.</description>
          </group>
          <group group_id="O7">
            <title>Napabucasin Plus Irinotecan</title>
            <description>All participants who were enrolled to Arm G to receive napabucasin administered orally, twice daily, in combination with irinotecan 180 mg/m2, administered intravenously starting on Day 1 of Cycle 1, following the first dose of napabucasin. This regimen was repeated every 14 days thereafter. Patients in this group had a baseline scan and at least one assessment approximately 8 weeks from baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control Rate</title>
          <description>To determine the anti-tumor activity (specifically the disease control rate) of napabucasin administered in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with and without bevacizumab, or regorafenib, or irinotecan. Percentage of participants with a documented complete response, partial response and stable disease based on RECIST 1.1.</description>
          <population>Patients who received at least 1 cycle of study treatment and had at least 1 disease assessment following the initiation of therapy. Patients missing imaging assessment following the initiation of treatment are not included in the assessment for DCR.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="105"/>
                <count group_id="O5" value="23"/>
                <count group_id="O6" value="32"/>
                <count group_id="O7" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.7"/>
                    <measurement group_id="O2" value="76.2"/>
                    <measurement group_id="O3" value="55.3"/>
                    <measurement group_id="O4" value="65.7"/>
                    <measurement group_id="O5" value="87.0"/>
                    <measurement group_id="O6" value="34.4"/>
                    <measurement group_id="O7" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Control Rate of Patients With FOLFIRI/XELIRI-refractory Metastatic Colorectal Cancer</title>
        <description>To determine the disease control rate of napabucasin administered in combination with FOLFIRI in patients with FOLFIRI/XELIRI-refractory metastatic colorectal cancer. Percentage of participants with a documented complete response, partial response and stable disease based on RECIST 1.1.</description>
        <time_frame>From the date of first treatment, every 8 weeks, until the date of first documented objective disease progression, up to 24 months</time_frame>
        <population>Patients with FOLFIRI/XELIRI refractory metastatic colorectal cancer who received at least 1 cycle of study treatment and had at least 1 disease assessment following the initiation of therapy. Patients missing imaging assessment following the initiation of treatment are not included in the assessment for DCR.</population>
        <group_list>
          <group group_id="O1">
            <title>Napabucasin Plus FOLFIRI</title>
            <description>All participants who were enrolled to Arm D to receive napabucasin administered orally, twice daily, in combination with FOLFIRI regimen. Irinotecan 180 mg/m2 together with leucovorin 400 mg/m2 was administered intravenously starting on Day 1 of Cycle 1, following the first dose of napabucasin. A 5-FU 400 mg/m2 bolus was administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m2/day (total 2400 mg/m2) by continuous infusion. This regimen was repeated every 14 days thereafter.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control Rate of Patients With FOLFIRI/XELIRI-refractory Metastatic Colorectal Cancer</title>
          <description>To determine the disease control rate of napabucasin administered in combination with FOLFIRI in patients with FOLFIRI/XELIRI-refractory metastatic colorectal cancer. Percentage of participants with a documented complete response, partial response and stable disease based on RECIST 1.1.</description>
          <population>Patients with FOLFIRI/XELIRI refractory metastatic colorectal cancer who received at least 1 cycle of study treatment and had at least 1 disease assessment following the initiation of therapy. Patients missing imaging assessment following the initiation of treatment are not included in the assessment for DCR.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival of Patients With FOLFIRI/XELIRI-refractory Metastatic Colorectal Cancer</title>
        <description>The effect of napabucasin given in combination with FOLFIRI on Progression Free Survival (PFS) of patients with FOLFIRI/XELIRI-refractory metastatic colorectal cancer. PFS of patients with FOLFIRI/XELIRI-refractory metastatic colorectal cancer.</description>
        <time_frame>The time from the date of first treatment to the date of first documentation of disease progression or death due to any cause, up to thirty six months</time_frame>
        <population>Analysis limited to a subset of group D in which patients had FOLFIRI/XELIRI refractory metastatic colorectal cancer. Patients in this subgroup also had a baseline scan and at least 1 on study scan or died from any cause.</population>
        <group_list>
          <group group_id="O1">
            <title>Napabucasin Plus FOLFIRI</title>
            <description>Napabucasin administered orally, twice daily, in combination with FOLFIRI regimen. Irinotecan 180 mg/m2 together with leucovorin 400 mg/m2 was administered intravenously starting on Day 1 of Cycle 1, following the first dose of napabucasin. A 5-FU 400 mg/m2 bolus was administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m2/day (total 2400 mg/m2) by continuous infusion. This regimen was repeated every 14 days thereafter. Patients in this group had a baseline scan and at least one on study scan or died from any cause.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival of Patients With FOLFIRI/XELIRI-refractory Metastatic Colorectal Cancer</title>
          <description>The effect of napabucasin given in combination with FOLFIRI on Progression Free Survival (PFS) of patients with FOLFIRI/XELIRI-refractory metastatic colorectal cancer. PFS of patients with FOLFIRI/XELIRI-refractory metastatic colorectal cancer.</description>
          <population>Analysis limited to a subset of group D in which patients had FOLFIRI/XELIRI refractory metastatic colorectal cancer. Patients in this subgroup also had a baseline scan and at least 1 on study scan or died from any cause.</population>
          <units>months</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.82" lower_limit="11.42" upper_limit="32.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival of Patients With FOLFIRI/XELIRI-refractory Metastatic Colorectal Cancer</title>
        <description>The effect of napabucasin given in combination with FOLFIRI on Overall Survival (OS) of patients with FOLFIRI/XELIRI-refractory metastatic colorectal cancer.</description>
        <time_frame>4 weeks after the patient has been off study treatment, every 3 months thereafter until death, the study closes, up to 36 months.</time_frame>
        <population>Analysis limited to a subset of group D in which patients had FOLFIRI/XELIRI refractory metastatic colorectal cancer.</population>
        <group_list>
          <group group_id="O1">
            <title>Napabucasin Plus FOLFIRI</title>
            <description>Napabucasin administered orally, twice daily, in combination with FOLFIRI regimen. Irinotecan 180 mg/m2 together with leucovorin 400 mg/m2 was administered intravenously starting on Day 1 of Cycle 1, following the first dose of napabucasin. A 5-FU 400 mg/m2 bolus was administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m2/day (total 2400 mg/m2) by continuous infusion. This regimen was repeated every 14 days thereafter . The patients in this subgroup were assessed to have FOLFIRI/XELIRI refractory metastatic colorectal cancer prior to enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival of Patients With FOLFIRI/XELIRI-refractory Metastatic Colorectal Cancer</title>
          <description>The effect of napabucasin given in combination with FOLFIRI on Overall Survival (OS) of patients with FOLFIRI/XELIRI-refractory metastatic colorectal cancer.</description>
          <population>Analysis limited to a subset of group D in which patients had FOLFIRI/XELIRI refractory metastatic colorectal cancer.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.97" lower_limit="6.80" upper_limit="11.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious and Other Adverse Events were assessed from the date of first treatment through 30 days of the last administration of study drug, an average of 4 months. All-Cause Mortality was assessed from the date of first treatment until death, up to 36 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Napabucasin Plus FOLFOX6</title>
          <description>All participants who received at least 1 dose of napabucasin administered orally, twice daily, in combination with FOLFOX6 regimen administered every 14 days. The regimen consisted of oxaliplatin 85 mg/m2 together with leucovorin 400 mg/m2 administered intravenously starting on Day 1 of Cycle 1, after the first daily dose of napabucasin. A 5-FU 400 mg/m2 bolus was administered intravenously immediately following oxaliplatin/leucovorin infusion, followed by 5-FU 1200 mg/m2/day (total 2400 mg/m2 over 46-48 hours) by continuous intravenous (IV) infusion.</description>
        </group>
        <group group_id="E2">
          <title>Napabucasin Plus FOLFOX6 Plus Bevacizumab</title>
          <description>All participants who received at least 1 dose of napabucasin administered orally, twice daily, in combination with FOLFOX6 plus bevacizumab regimen administered every 14 days. The regimen consisted of oxaliplatin 85 mg/m2 together with leucovorin 400 mg/m2 administered intravenously over 2 hours starting on Day1 of Cycle 1, following the first daily dose of napabucasin. A 5-FU 400 mg/m2 bolus was administered intravenously immediately following oxaliplatin/leucovorin infusion, followed by 5-FU 1200 mg/m2/day (total 2400 mg/m2 over 46-48 hours) by continuous IV infusion. Bevacizumab 5 mg/kg was administered intravenously following the oxaliplatin/leucovorin infusion.</description>
        </group>
        <group group_id="E3">
          <title>Napabucasin Plus CAPOX</title>
          <description>All participants who received at least 1 dose of napabucasin administered orally, twice daily, in combination with CAPOX regimen. The CAPOX regimen was administered orally (capecitabine) and by IV (oxaliplatin). Starting on Day 1 of Cycle 1, capecitabine 850 mg/m2 was administered orally BID following the first daily dose of napabucasin for 14 consecutive days and repeated every 21 days. Oxaliplatin 130 mg/m2 was administered intravenously over 2 hours, following the first daily dose of napabucasin starting on Day 1 of Cycle 1 and repeated every 21 days thereafter. If capecitabine was tolerated at the 850 mg/m2 BID dose, the dosage could have been increased to 1000 mg/m2 BID as tolerated after the first cycle.</description>
        </group>
        <group group_id="E4">
          <title>Napabucasin Plus FOLFIRI</title>
          <description>All participants who received at least 1 dose of napabucasin administered orally, twice daily, in combination with FOLFIRI regimen. Irinotecan 180 mg/m2 together with leucovorin 400 mg/m2 was administered intravenously starting on Day 1 of Cycle 1, following the first dose of napabucasin. A 5-FU 400 mg/m2 bolus was administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m2/day (total 2400 mg/m2) by continuous infusion. This regimen was repeated every 14 days thereafter.</description>
        </group>
        <group group_id="E5">
          <title>Napabucasin Plus FOLFIRI Plus Bevacizumab</title>
          <description>All participants who received at least 1 dose of napabucasin administered orally, twice daily, in combination with FOLFIRI plus bevacizumab regimen. Irinotecan 180 mg/m2 together with leucovorin 400 mg/m2 was administered intravenously starting on Day 1 of Cycle 1, following the first dose of napabucasin. A 5-FU 400 mg/m2 bolus was administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5 FU 1200 mg/m2/day (total 2400 mg/m2) by continuous infusion. Bevacizumab 5 mg/kg was administered intravenously following the irinotecan/leucovorin infusion. This regimen was repeated every 14 days thereafter.</description>
        </group>
        <group group_id="E6">
          <title>Napabucasin Plus Regorafenib</title>
          <description>All participants who received at least 1 dose of napabucasin administered orally, twice daily, in combination with regorafenib 120 mg, administered orally once daily with a low-fat meal, starting on Day 1 of Cycle 1 for 21 consecutive days of every 28 days thereafter. If regorafenib was tolerated in the first cycle, the dosage could have been increased to 160 mg once daily as tolerated after the first cycle.</description>
        </group>
        <group group_id="E7">
          <title>Napabucasin Plus Irinotecan</title>
          <description>All participants who received at least 1 dose of napabucasin administered orally, twice daily, in combination with irinotecan 180 mg/m2, administered intravenously starting on Day 1 of Cycle 1, following the first dose of napabucasin. This regimen was repeated every 14 days thereafter.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="82" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="129" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="50" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="58" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Enterocutaneous fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Obstruction gastric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Large instestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Megacolon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Salmonella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pyuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Peritonitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Viral sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>stoma site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>gastroenteritis radiation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>malignant pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage intranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>pelvic venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="87" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="156" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="40" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="54" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="75" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="139" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="39" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="42" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="100" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="37" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="26" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="76" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="32" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="58" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="26" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="92" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="29" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Temperature intolerance</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Urine ketone body present</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Urine leukocyte esterase positive</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tegan Nguyen</name_or_title>
      <organization>Sumitomo Dainippon Pharma Oncology</organization>
      <phone>617-674-8745</phone>
      <email>tnguyen@bostonbiomedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

